Santen Pharmaceutical Co (MEX:4536N) Interest Expense: MXN-226 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:4536N Santen Pharmaceutical Co Ltd MEX:4536N
80 GF Score
Price MXN339.23
GF Value MXN299.21
View Full Analysis

What is Santen Pharmaceutical Co Interest Expense?

Santen Pharmaceutical Co MEX:4536N 80 Interest Expense is MXN-226 Mil as of Jun. 2026. GuruFocus rates MEX:4536N with a GF Score™ of 80/100 and a GF Value™ of MXN299.21.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Santen Pharmaceutical Co's interest expense for the three months ended in Jun. 2026 was MXN -80 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was MXN-226 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Santen Pharmaceutical Co's Operating Income for the three months ended in Jun. 2026 was MXN 881 Mil. Santen Pharmaceutical Co's Interest Expense for the three months ended in Jun. 2026 was MXN -80 Mil. Santen Pharmaceutical Co's Interest Coverage for the quarter that ended in Jun. 2026 was 11.00. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Santen Pharmaceutical Co  (MEX:4536N) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Santen Pharmaceutical Co's Interest Expense for the three months ended in Jun. 2026 was MXN-80 Mil. Its Operating Income for the three months ended in Jun. 2026 was MXN881 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2026 was MXN0 Mil.

Santen Pharmaceutical Co's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Jun. 2026 )/Interest Expense (Q: Jun. 2026 )
=-1*880.97/-80.098
=11.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Santen Pharmaceutical Co Interest Expense Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co Interest Expense Chart

Santen Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -203.01 -202.14 -295.11 -372.77 -226.60

Santen Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -97.61 -51.49 -36.72 -58.18 -80.10
MEX:4536N
80GF Score
Santen Pharmaceutical Co Ltd MEX:4536N
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santen Pharmaceutical Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-226 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of MXN-226 Mil mean?
Santen Pharmaceutical Co (MEX:4536N) has a Interest Expense of MXN-226 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's Interest Expense too high?
Santen Pharmaceutical Co's current Interest Expense is MXN-226 Mil. Overall, Santen Pharmaceutical Co has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Interest Expense compare to LLY and JNJ?
Santen Pharmaceutical Co's Interest Expense of MXN-226 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Interest Expense is MXN-226 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Santen Pharmaceutical Co (MEX:4536N) has a current Interest Expense of MXN-226 Mil. The stock's GF Value™ is MXN299.21, compared to a current price of MXN339.23 — trading 13.4% above its estimated fair value. The current Interest Expense is MXN-226 Mil. Santen Pharmaceutical Co's overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Santen Pharmaceutical Co (MEX:4536N), the current Interest Expense is MXN-226 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (MEX:4536N) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of MXN339.23 is trading 13.4% above its estimated GF Value™ of MXN299.21.

Key valuation signals for MEX:4536N:

  • Interest Expense: MXN-226 Mil
  • GF Value™: MXN299.21 vs. price of MXN339.23 (13.4% above fair value)
  • GF Score™: 80/100

No single metric tells the full story. See the MEX:4536N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santen Pharmaceutical Co Business Description

Other Exchanges SNPHY:USA4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
80GF Score

Get the complete analysis for MEX:4536N

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN339.23
Price
MXN299.21
GF Value